Dynamic Technology Lab Private Ltd Acquires Shares of 12,474 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Dynamic Technology Lab Private Ltd bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,474 shares of the company’s stock, valued at approximately $174,000.

A number of other institutional investors have also recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the last quarter. Quest Partners LLC raised its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after purchasing an additional 7,668 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Day One Biopharmaceuticals during the second quarter valued at $113,000. Point72 DIFC Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the second quarter valued at $124,000. Finally, Hsbc Holdings PLC bought a new stake in Day One Biopharmaceuticals in the 2nd quarter worth about $163,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $16.03, for a total transaction of $180,257.35. Following the transaction, the insider now owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. The trade was a 1.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 51,745 shares of company stock valued at $775,867 over the last quarter. 8.40% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $13.84 on Tuesday. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.51 and a 1-year high of $18.07. The company’s fifty day simple moving average is $14.32 and its 200-day simple moving average is $14.13. The stock has a market capitalization of $1.40 billion, a PE ratio of -13.38 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter last year, the firm posted ($0.54) earnings per share. As a group, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. JPMorgan Chase & Co. decreased their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.